<< Modern techniques can reduce current shortage of H1N1 vaccine in the U.S. | Comprehensive guide on Italy’s medicated skin care industry >>
Read in | English | 한국어 | Finnish

Recipients of the second round of funding under CLL/SLL Research Initiative announced by LRF

Published on October 29, 2009 at 2:49 AM · No Comments

Second round of grants brings overall total to $2,375,000

The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative.

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are the same disease with slightly different manifestations. Where the cancerous cells gather determines whether it is called CLL or SLL. When the cancer cells are primarily found in the lymph nodes, lima bean shaped structures of the lymphatic system, an essential part of the body's immune system, it is called SLL. When most of the cancer cells are in the bloodstream and the bone marrow, it is called CLL.

John Balan, founder of the CLL Information Group with membership of approximately 1000 patients and caregivers, expressed the group's delight with these two awards. "We have a great deal of respect for the work that Drs. Kipps and Frank have been doing with CLL. These two awards will only augment what they have already done and add to the arsenal of treatments available to patients."

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading